## Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

## Listing of Claims

- 1. (Currently Amended) A method for the treatment of a cancer comprising co-administering an anti-tumor antibody <u>directed against the MN antigen</u> and a cytokine to a subject in need thereof, wherein the cytokine is administered continuously or repeatedly in a low-dose form.
- 2. (Currently Amended) A method for the treatment of a cancer comprising co-administering an anti-tumor antibody <u>directed against the MN antigen</u> and cytokine to a subject in need thereof, wherein the method comprises:
- (a) a first treatment stage comprising administering a low-dose cytokine, and
- (b) a second treatment stage comprising co-administering an the anti-tumor antibody and a low-dose cytokine.
- 3. (Previously Presented) The method of claim 1, wherein the low-dose cytokine comprises a dose which is pharmaceutically effective in the substantial absence of NIC CTC toxicity grade 3 or higher.
- 4. (Previously Presented) The method according to claim 1 comprising a daily administration of a low-dose cytokine.

- 5. (Previously Presented) The method according to claim 1 wherein the cytokine is selected from interleukins and interferons.
- 6. (Original) The method of claim 5 wherein the cytokine is IL-2.
- 7. (Original) The method of claim 6 wherein the dose of IL-2 is in the range of from 1-10 MIU daily.
- 8. (Original) The method of claim 5 wherein the cytokine is IFN-α.
- 9. (Original) The method of claim 8 wherein the dose of IFN- $\alpha$  is in the range of from 1-10 MIU three times a week.
- 10. (Previously Presented) The method of claim 1 wherein the cytokine is administered in a substantially constant dose during the treatment.
- 11. (Previously Presented) The method of claim 1 wherein the cytokine is administered in a variable dose during the treatment.
- 12. (Previously Presented) The method of claim 1 wherein the cytokine is administered subcutaneously.

- 13. (Currently Amended) The method of claim 1 wherein the antitumor antibody is selected from antibodies directed against the MN (G250) antigent antigen.
- 14. (Previously Presented) The method of claim 1 wherein the antitumor antibody is a chimeric or humanized G250 antibody or a fragment thereof.
- 15. (Previously Presented) The method of claim 1 wherein the antitumor antibody is administered in intervals of from 5-20 days.
- 16. (Original) The method of claim 2 wherein the first treatment stage comprises 5-20 days.
- 17. (Original) The method of claim 2 wherein the second treatment stage comprises 50-200 days.